Program
Ketamine
Also written as “Ketamine Hydrochloride”, “Ketamine (0.25 mg/kg)” and “Ketamine (0.5 mg/kg)”.
Its studies are mostly in Depressive Disorder, Major · Depression · Schizophrenia · Depressive Disorder, Treatment-Resistant · Bipolar Disorder, led by 15 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 50 open or running | phase 2since Jun 22, 2012 | Jul 15, 2010 | none ahead |
| Egymedicalpedia | 20 open or running | phase 1since Jun 21, 2022 | Jun 21, 2022 | none ahead |
| cch-pharmaceuticals | 10 open or running | phase 2since Nov 25, 2019 | Nov 25, 2019 | none ahead |
| dr-horst-schmidt-klinik-gmbh | 10 open or running | no phasesince Aug 12, 2016 | Aug 12, 2016 | none ahead |
| ehave-inc | 10 open or running | phase 4since Aug 9, 2022 | Aug 9, 2022 | none ahead |
| ERP Biomarker Qualification Consortium | 10 open or running | early phase 1since May 28, 2021 | May 28, 2021 | none ahead |
| Field Trip Health | 10 open or running | phase 4since Oct 12, 2022 | Oct 12, 2022 | none ahead |
| Homeostasis Therapeutics | 10 open or running | phase 1since Jan 12, 2021 | Jan 12, 2021 | none ahead |
| javelin-pharmaceuticals | 10 open or running | phase 1since Apr 16, 2008 | Apr 16, 2008 | none ahead |
| NeuroRx | 11 open or running | phase 3since Jan 5, 2018 | Jan 5, 2018 | none ahead |
| neurowave-systems-inc | 10 open or running | phase 1since Dec 29, 2016 | Dec 29, 2016 | none ahead |
| PharmaTher | 10 open or running | phase 2since May 25, 2021 | May 25, 2021 | none ahead |
| Seelos Therapeutics | 10 open or running | phase 2since Dec 9, 2020 | Dec 9, 2020 | none ahead |
| Soterix Medical | 10 open or running | phase 1since Dec 15, 2025 | Dec 15, 2025 | none ahead |
| trudiagnostic | 10 open or running | phase 2since Mar 14, 2022 | Mar 14, 2022 | none ahead |
Also a collaborator on its studies: target-health-inc, Alkermes, anavex-life-sciences-corp, Astellas Pharma, H. Lundbeck, Merck, Novartis, Supernus Pharmaceuticals and Takeda.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Apr 16, 2008.
- Dec 29, 2016neurowave-systems-inc's first study: phase 1 study in AnesthesiaNew to neurowave-systems-incneurowave-systems-inc · NCT03009409 · 60 enrolled · Canada
- Jan 5, 2018NeuroRx's first study: phase 3 study in Bipolar DisorderNew to NeuroRxNeuroRx · NCT03396601 · 150 enrolled · United States
- Jan 4, 2019Phase 1 study in HealthyJohnson & Johnson · NCT03808259 · 96 enrolled · Belgium
- Nov 25, 2019cch-pharmaceuticals's first study: phase 2 study in Cluster HeadacheNew to cch-pharmaceuticalscch-pharmaceuticals · NCT04179266 · 23 enrolled · Denmark
- Dec 9, 2020Seelos Therapeutics's first study: phase 2 study in Depressive Disorder, MajorNew to Seelos TherapeuticsSeelos Therapeutics · NCT04669665 · 164 enrolled · United States
- Jan 12, 2021Homeostasis Therapeutics's first study: phase 1 study in Anorexia NervosaNew to Homeostasis TherapeuticsHomeostasis Therapeutics · NCT04714541 · 5 enrolled · United States
- May 25, 2021PharmaTher's first study: phase 2 study in DyskinesiasNew to PharmaTherPharmaTher · NCT04912115 · 30 enrolled · United States
- May 28, 2021ERP Biomarker Qualification Consortium's first study: early phase 1 study in HealthyNew to ERP Biomarker Qualification ConsortiumERP Biomarker Qualification Consortium · NCT04928703 · 33 enrolled · United States
- Mar 14, 2022trudiagnostic's first study: phase 2 study in DepressionNew to trudiagnostictrudiagnostic · NCT05294835 · 20 enrolled · United States
- Jun 21, 2022Egymedicalpedia's first study: phase 1 study in SurgeryNew to EgymedicalpediaEgymedicalpedia · NCT05444036 · 60 enrolled · Egypt
- Aug 9, 2022ehave-inc's first study: phase 4 study in Depressive Disorder, MajorNew to ehave-incehave-inc · NCT05506462 · 35 enrolled
- Oct 12, 2022Field Trip Health's first study: phase 4 study in DepressionNew to Field Trip HealthField Trip Health · NCT05604794 · 1,806 enrolled · United States, Canada
- Oct 24, 2022Phase 1 study in NephrectomyEgymedicalpedia · NCT05596669 · 100 enrolled · Egypt
- Dec 15, 2025Soterix Medical's first study: phase 1 study in Depressive Disorder, Treatment-ResistantNew to Soterix MedicalSoterix Medical · NCT07307768 · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07307768Depressive Disorder, Treatment-Resistant · United States | 1 | Withdrawn | Soterix Medical | Dec 1, 2027 | 0 |
| NCT05596669Nephrectomy · Egypt | 1 | Completed | Egymedicalpedia | May 1, 2022 | 100 |
| NCT05604794Depression · United States, Canada | 4 | Completed | Field Trip Health | Jun 16, 2022 | 1,806 |
| NCT05506462Depressive Disorder, Major | 4 | UNKNOWN | ehave-inc | Jan 2024 | 35 |
| NCT05444036Surgery · Egypt | 1 | Completed | Egymedicalpedia | May 15, 2019 | 60 |
| NCT05294835Depression · United States | 2 | UNKNOWN | trudiagnostic | Dec 31, 2022 | 20 |
| NCT04928703Healthy · United States | Early 1 | Completed | ERP Biomarker Qualification Consortium | Dec 12, 2022 | 33 |
| NCT04912115Dyskinesias · United States | 2 | Suspended | PharmaTher | Dec 30, 2023 | 30 |
| NCT04714541Anorexia Nervosa · United States | 1 | Completed | Homeostasis Therapeutics | Jul 26, 2022 | 5 |
| NCT04669665Depressive Disorder, Major · United States | 2 | Completed | Seelos Therapeutics | Jun 17, 2023 | 164 |
| NCT04179266Cluster Headache · Denmark | 2 | Completed | cch-pharmaceuticals | May 12, 2020 | 23 |
| NCT03808259Healthy · Belgium | 1 | Completed | Johnson & Johnson | Sep 4, 2019 | 96 |
| NCT03396601Bipolar Disorder · United States | 3 | Active, not recruiting | NeuroRx | Dec 31, 2024 | 150 |
| NCT03009409Anesthesia · Canada | 1 | Completed | neurowave-systems-inc | Oct 17, 2018 | 60 |
| NCT03105765Acute Pain · Germany | – | Completed | dr-horst-schmidt-klinik-gmbh | Aug 2014 | 200 |
| NCT01957410Depressive Disorder, Major · United States | 2 | Terminated | Johnson & Johnson | Sep 2015 | 13 |
| NCT01809340Depressive Disorder · Belgium, France, Netherlands and more | 2 | Terminated | Johnson & Johnson | Jul 2014 | 29 |
| NCT01627782Depressive Disorder, Major · United States | 2 | Completed | Johnson & Johnson | Sep 12, 2013 | 68 |
| NCT01165294Schizophrenia | 1 | Completed | Johnson & Johnson | 24 | |
| NCT00662883Healthy · United States | 1 | Completed | javelin-pharmaceuticals | Feb 2008 | 18 |
How it is read
Names in the registry
- “Ketamine”, 12 entries
- “Ketamine Hydrochloride”, 2 entries
- “Ketamine (0.25 mg/kg)”, 1 entry
- “Ketamine (0.5 mg/kg)”, 1 entry
- “Ketamine (0.75 mg/kg)”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 4 studies
- Depression, 2 studies
- Schizophrenia, 2 studies
- Depressive Disorder, Treatment-Resistant, 1 study
- Bipolar Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.